MIT

CRISPR, Intellia, Caribou and ERS Genomics provide update on CRISPR/Cas9 U.S. patent

Friday, February 17, 2017

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics provided an update on the Patent Trial & Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) decision on the motions filed by the University of California, the University of Vienna and Dr. Emmanuelle Charpentier (collectively, UC), on one hand, and the Broad Institute, Harvard University and the Massachusetts Institute of Technology (collectively, Broad), on the other, in the interference proceeding relating to CRISPR/Cas9 genome editing technology.

[Read More]

Koch Institute receives $1M from Takeda to support immuno-oncology research

Friday, February 10, 2017

Takeda Pharmaceutical and the Koch Institute for Integrative Cancer Research at MIT jointly announced that Takeda will support groundbreaking science in immuno-oncology at the Koch Institute. Over the next two years, the $1 million gift will help to build upon the research currently being conducted by the Institute to investigate the role of the immune response in cancer and develop potential novel treatments.

[Read More]

IBM Watson Health, Broad Institute launch research initiative

Friday, November 11, 2016

IBM Watson Health and the Broad Institute of MIT and Harvard have announced a research initiative aimed at discovering the basis of cancer drug resistance. The five year, $50 million project will study thousands of drug resistant tumors and draw on Watson’s computational and machine learning methods to help researchers understand how cancers become resistant to therapies. The anonymized data will be made available to the scientific community to catalyze research worldwide.

[Read More]

C4 Therapeutics completes core scientific leadership team

Wednesday, September 7, 2016

C4 Therapeutics (C4T) has announced details of the leadership team recruited to develop a new class of broadly applicable small molecule drugs for degrading disease-relevant proteins for therapeutic benefit. The leadership team includes Isabel Chiu, Ph.D., as senior vice president of Translational Sciences and Alliance Management, Stewart Fisher, Ph.D., as senior vice president of Discovery Sciences, Tim Heffernan, Ph.D., as senior vice president of Biology, and Christopher Nasveschuk, Ph.D., as vice president of Chemistry.

[Read More]

ORIG3N adds Melissa May as VP of product strategy

Friday, May 20, 2016

ORIG3N, a pioneer in the field of regenerative medicine, has added Melissa May as the company’s vice president of product strategy to establish partnerships and collaborations to bring in non-dilutive funding that will support R&D to develop future product offerings. In addition, May will play a role in the strategy and channel development of ORIG3N’s life science products, as well as LifeProfiles, which are genetic analysis available for consumers.

[Read More]